Skip to main content

Clifford Chance
Bryan J.  Luchs

Bryan J. Luchs

Partner

Partner
Bryan J. Luchs

Bryan J. Luchs is a Corporate M&A partner in New York.

His practice includes representing acquirers, targets, boards of directors, special committees, investors and investment banks in complex domestic and cross-border deals including negotiated, unsolicited and in public and private transactions. Bryan has advised across a range of industries and has extensive experience in the healthcare and life sciences sector.

  • Falcon Capital Acquisition Corp. (NASDAQ: FCAC), a SPAC, in its US$3.9 billion business combination with Sharecare, Inc., a digital health company based in Georgia.
  • InterPrivate III Financial Partners Inc. (NYSE: IPVF), a SPAC, in its US$2.3 billion acquisition of Aspiration Partners, Inc., a global leader in Sustainability as a Service solutions for consumers and companies.
  • DFP Healthcare Acquisitions Corp. (NASDAQ: DFPH, DFPHW), a SPAC, in its US$842 million business combination with The Oncology Institute, a US market-leader in value-based oncology care.
  • Deerfield Healthcare Technology Acquisitions Corp. (NASDAQ: DFHT), a SPAC, in its US$614 million business combination with CareMax Medical Group, L.L.C. and IMC Medical Group Holdings LLC, creating a technology-enabled care platform providing value-based care and chronic disease management to seniors.
  • FS Development Corp. II (NASDAQ: FSII), a SPAC, in its US$276.2 million business combination with Pardes Biosciences, Inc., an early stage biopharmaceutical company developing a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
  • Helix Acquisition Corp. (NASDAQ: HLXA), a SPAC, in its US$230 million business combination with MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases.  
  • FS Development Corp. (NASDAQ: FSDC), a SPAC, in its US$216 million business combination with Gemini Therapeutics, Inc., a clinical stage precision medicine company developing treatments for genetically defined age-related macular degeneration.
  • Lantheus Holdings, Inc. (NASDAQ: LNTH) in its acquisition of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX).
  • Roche Diagnostics Corp. in the sale of Roche Health Solutions Inc. to CardioNet, LLC, a wholly owned subsidiary of BioTelemetry, Inc.
  • Hikma Pharmaceuticals PLC in its US$2.65 billion acquisition of the US-based generic drugs businesses, Roxane Laboratories and Boehringer Ingelheim Roxane, from German drug maker Boehringer Ingelheim.
  • Hikma Pharmaceuticals PLC in its acquisition of assets relating to a portfolio of six injectable products for commercialization in certain European markets from Pfizer.
  • Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a world leader in musculoskeletal health solutions, in its US$14 billion deal to acquire Biomet, Inc., one of the world's leading medical device manufacturers.
  • Omnicare, Inc. in its US$12.7 billion acquisition by CVS Health, as well as Omnicare's prior US$1.8 billion unsolicited acquisition of NeighborCare Inc. and US$460 million unsolicited acquisition of NCS HealthCare, Inc.
  • Sony Corporation of America in its US$2.2 billion acquisition of EMI Music Publishing with a consortium of acquirors; acquisition of the 50% interest in Sony/ATV Music Publishing LLC held by the Estate of Michael Jackson.
  • King Pharmaceuticals, Inc. in its US$1.6 billion unsolicited acquisition of Alpharma Inc.
  • Roivant Sciences Ltd. on several portfolio company transactions.
  • Certares LP, a private equity group with a focus in the travel, transportation and hospitality industry, in the acquisition of 50 percent of the equity of AmaWaterways, a premium European river cruise operator; and in its acquisition of Guardian Alarm, a super-regional security provider.
  • Special Committee of the Board of Directors of GFI Group Inc., (NYSE: GFIG), the New York brokerage and clearing house, in the successful completion of a tender offer by BGC Partners, Inc. (NASDAQ: BGCP), a leading global brokerage company servicing the financial and real estate markets, for the outstanding shares of GFI, resulting in an equity value of approximately US$780 million and an enterprise value of US$1 billion. 
  • J.F. Hillebrand USA Holding, Inc., a portfolio company of Cobepa SA (the Belgian investment company), in its acquisition of a majority of the outstanding equity interests of Satellite Logistics Group, a leading beverage supply chain logistics business.
  • Nordic Capital, DLJ Merchant Banking, Avista Capital and other private equity sponsors in their US$1.525 billion sale of Fougera Pharmaceuticals to Sandoz.
  • Nestlé México, SA de CV in its acquisition of a majority stake in Terrafertil, a company selling natural, organic, plant-based foods and healthy snacks.

The above reflects experience from Bryan's prior firm.

News and client work

View all news and client work featuring Bryan Luchs

Contact details

Career & qualifications

  • Pepperdine University (BA) 1988
  • University of Pennsylvania (MA) 1997
  • University of Pennsylvania Law School (JD) 1996
  • Admitted as Attorney-at-Law in New York 1999
  • Joined Clifford Chance as partner 2025

Awards and citations

  • Leading Lawyer for M&A in the United States, Euromoney, 2021